LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Akcijų sąrašas・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.24 5.66

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.15

Max

2.31

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-3.8M -43M
Pelnas, tenkantis vienai akcijai	-0.18
Darbuotojai	150
EBITDA	-3.9M -43M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+310.85% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-12

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-96M 690M
Ankstesnė atidarymo kaina	-3.42
Ankstesnė uždarymo kaina	2.24

Naujienos nuotaikos

By Acuity

100%

328 / 344 reitingas Healthcare

Allogene Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-27 21:33; UTC

Uždarbis

Correction to Salesforce 1Q Sales, Profit Rise Article

2026-05-27 21:00; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare Agrees to Buy The College of Health Care Professions

2026-05-27 20:18; UTC

Uždarbis

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

2026-05-27 23:49; UTC

Rinkos pokalbiai

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

2026-05-27 23:39; UTC

Rinkos pokalbiai

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

2026-05-27 23:34; UTC

Rinkos pokalbiai

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

2026-05-27 23:34; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-27 23:08; UTC

Rinkos pokalbiai

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

2026-05-27 22:21; UTC

Rinkos pokalbiai

Salesforce Lays Out AI Monetization Strategy -- Market Talk

2026-05-27 21:29; UTC

Karštos akcijos

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

2026-05-27 21:08; UTC

Uždarbis

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

2026-05-27 21:02; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

2026-05-27 20:59; UTC

Įsigijimai, susijungimai, perėmimai

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

2026-05-27 20:55; UTC

Uždarbis

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

2026-05-27 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-27 20:48; UTC

Uždarbis

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

2026-05-27 20:45; UTC

Uždarbis

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

2026-05-27 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Webster Financial Stockholders Approve Sale to Banco Santander

2026-05-27 20:32; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026-05-27 20:32; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

2026-05-27 20:32; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

2026-05-27 20:30; UTC

Uždarbis

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

2026-05-27 20:30; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

2026-05-27 20:22; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026-05-27 20:16; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026-05-27 20:13; UTC

Uždarbis

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

2026-05-27 20:13; UTC

Uždarbis

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

2026-05-27 20:13; UTC

Uždarbis

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

2026-05-27 20:12; UTC

Uždarbis

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

2026-05-27 20:12; UTC

Uždarbis

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Akcijų palyginimas

Kainos pokytis

Allogene Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

310.85% į viršų

12 mėnesių prognozė

Vidutinis 8.71 USD 310.85%

Aukščiausias 14 USD

Žemiausias 3.85 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Allogene Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

Pirkti

Laikyti

Parduoti

Remiantis 14 analitikų, pateikusių Allogene Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

328 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.